[ad_1]
The United States Food and Drug Administration (FDA) has issued a formal authorization for the use of emergency medications to treat antiviral medications “REMDIVIVIR” for the treatment of suspected or clinically confirmed patients with COVID-19 in adults and children in hospitals with serious illnesses.
The Food and Drug Administration’s emergency statement to remdesivir, which came two days after clinical experience of the promising results from the National Institutes of Health, is an important step forward in the fight against the Corona virus.
FDA approval for the drug Reimserv
Permission for use in emergencies allows the distribution of remdesivir to treat suspected or laboratory confirmed corona patients in adults and children in hospitals with serious illness, and severe illness is defined as patients with low blood oxygen levels or needing oxygen therapy or respiratory support More intense as a ventilator.
The text of the FDA statement says on its official website: “Based on evaluation of emergency use license standards and available scientific evidence, it has been determined that it is reasonable to believe that Remdesivir can be effective in treating of COVID-19, and that since there are no appropriate, approved or available alternative therapies available, Known and potential benefits of treating this dangerous or life-threatening virus Currently known and potential risks of drug use.
Ramesdevir
Emphasizing that important information on the use of remdesivir in the treatment of COVID-19 is available to healthcare providers and patients, including dosage instructions, possible side effects, and drug interactions. Possible side effects of the remedivir include: Increased levels of liver enzymes, which can be a sign of inflammation or damage to liver cells. And leak-related reactions, which can include low blood pressure, nausea, vomiting, sweating, and tremors.
The FDA previously allowed the investigational drug to be studied in clinical trials, as well as extended use for individual patients and through an expanded multi-patient access program coordinated by the Gilead Corporation.
